2-Phenylimidazopyridines, a new series of golgi compounds with potent antiviral activity

Journal of Medicinal Chemistry

Volumn 50, Issue 24, 2007, Pages 5984-5993

  Banie, Homayon ^a,b   Sinha, Anjana ^a   Thomas, Richard J ^a   Sircar, Jagadish C ^a   Richards, Mark L ^a  

^a AVANIR PHARMACEUTICALS   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PHENYLIMIDAZOPYRIDINE DERIVATIVE; ANTIVIRUS AGENT; IMIDAZOPYRIDINE DERIVATIVE; N [4 [6 (ADAMANTANECARBOXAMIDO) 3H IMIDAZO[4,5 C]PYRIDIN 2 YL]PHENYL]ADAMANTANECARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GOLGI COMPLEX; GUINEA PIG; HERPES; HUMAN; HUMAN CELL; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION; VIRUS STRAIN;

ADAMANTANE; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; FEMALE; GOLGI APPARATUS; GUINEA PIGS; HELA CELLS; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN E; MICE; MICE, INBRED BALB C; PYRIDINES; VERO CELLS; VIROLOGY;

EID: 37849022452     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0704907     Document Type: Article

References (24)

1. (a) Grant, R. M.; Hecht, F. M.; Warmerdam, M.; Liu, L.; Liegler, T.; Petropoulos, C J.; Hellman, N. S.; Chesney, M.; Busch, M. P.; Kahn, J. O. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288, 181-188.
2. (b) Iannello, A.; Debbeche, O.; Martin, E.; Attalah, L. H.; Samarani, S.; Ahmad, A. Viral strategies for evading antiviral cellular immune responses of the host. J. Leukoc. Biol. 2006, 79, 16-35.
3. Lippincott-Schwartz, J.; Yuan, L. C.; Bonifacino, J. S.; Klausner, R. D. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 1989, 56, 801-813.
4. Richards, M. L.; Lio, S. C.; Sinha, A.; Tieu, K. K.; Sircar, J. C. Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J. Med. Chem. 2004, 47, 6451-6454.
5. Richards, M. L.; Lio, S. C.; Sinha, A.; Banie, H.; Thomas, R. J.; Major, M.; Tanji, M.; Sircar, J. Substituted 2-phenyl-benzimidazole derivatives: novel compounds that suppress key markers of allergy. Eur. J. Med. Chem. 2006, 41, 950-969.
6. Lio, S. C.; Johnson, J.; Chatterjee, A.; Ludwig, J. W.; Millis, D.; Banie, H.; Sircar, J. C.; Sinha, A.; Richards, M. L. Disruption of Golgi processing by 2-(substituted phenyl) benzimidazole derivatives blocks cell proliferation and slows tumor growth. Cancer Chemother. Pharmacol. 2007, in press, Epub ahead of print.
7. Ludwig, J. W.; Richards, M. L. Targeting the secretory pathway for anti-inflammatory drug development. Curr. Top. Med. Chem. 2006, 6, 165-178.
8. (a) Ludwig, J. W.; Soneff, R-M.; Banie, H.; Marcantonio, D.; Scholz, W.; Galang, C.; Johnson, J.; Sircar, J. C.; Chatterjee, A.; Richards, M. L. Novel 2-phenyl-benzimidazole inhibitors of cytokines and cellular proliferation foster Golgi enzyme depletion through accelerated degradation. Eur. J. Pharmacol. 2007 (submitted for publication).
9. (b) Ludwig, J. W.; Banie, H.; Galang, C.; Lio, S. C.; Sircar, J. C. Richards, M. L. Golgi processing defect induced by AVP-13358 results in a loss of processing and expression of CD23. 2007 (Manuscript in preparation).
10. Marcelletti, J. F.; Katz, D. H. Elicitation of antigen-induced primary and secondary murine IgE antibody responses in vitro. Cell. Immunol. 1991, 135, 471-489.
11. (a) Beznoussenko, G. V.; Mironov, A. A. Models of intracellular transport and evolution of the Golgi complex. Anat. Rec. 2002, 268, 226-238.
12. (b) Pelham, H. R.; Rothman, J. E. The debate about transport in the Golgi-two sides of the same coin? Cell 2000, 102, 713-719.
13. (c) Marsh, B. J.; Howell, K. E. The mammalian Golgi-complex debates. Nat. Rev. Mol. Cell Biol. 2002, 3, 789-795.
14. (d) Storrie, B.; Pepperkok, R.; Nilsson, T. Breaking the COPI monopoly on Golgi recycling. Trends Cell Biol. 2000, 10, 385-391.
15. (a) Granzow, H.; Klupp, B. G.; Fuchs, W.; Veits, J.; Osterrieder, N.; Mettenleiter, T. C. Egress of alpha herpes viruses: comparative ultrastructural study. J. Virol. 2001, 75, 3675-3684.
16. (b) Husain, M.; Moss, B. Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles. J. Virol. 2001, 75, 7528-7542.
17. (c) Pettersson, R. F.; Melin, L. Synthesis, assembly and intracellular transport of Bunyaviridae membrane proteins. In The Bunyaviridae; Elliott, R. M., Ed.; Springer-Verlag: Berlin, Germany, 1996; pp 159-188.
18. (d) Gerrard, S. R.; Nichol, S. T. Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein. J. Virol. 2002, 76, 12200-12210.
19. (e) Klumperman, J.; Locker, J. K.; Meijer, A.; Horzinek, M. C.; Geuze, H. J.; Rottier, P. J. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J. Virol. 1994, 68, 6523-6534.
20. (f) Mackenzie, J. M.; Jones, M. K.; Westaway, E. G. Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. J. Virol. 1999, 73, 9555-9567.
21. de Jong, A. S.; Visch, H. J.; de Mattia, F.; van Dommelen, M. M.; Swarts, H. G.; Luyten, T.; Callewaert, G.; Melchers, W. J.; Willems, P. H.; van Kuppeveld, F. J. The coxsackievirus 2B protein increases efflux of ions from the endoplasmic reticulum and Golgi, thereby inhibiting protein trafficking through the Golgi. J. Biol. Chem. 2006, 281, 14144-14150.
22. Whitt, M. A.; Zagouras, P.; Crise, B.; Rose, J. K. A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. J. Virol. 1990, 64, 4907-4913.
23. Pelkmans, L.; Puntener, D.; Helenius, A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 2002, 296, 535-539.
24. Norkin, L. C.; Anderson, H. A.; Wolfrom, S. A.; Oppenheim, A. Caveolar endocytosis of simian virus 40 is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus disassembles. J. Virol. 2002, 76, 5156-5166.